Seizures represent abnormal, uncontrolled electrical disturbances in the brain, manifesting in a spectrum of symptoms from convulsions to altered consciousness. Understanding these events involves categorizing them into two primary types: focal seizures, originating in a specific brain area, and generalized seizures, involving both hemispheres. Further classification occurs based on characteristics like motor or sensory symptoms and awareness levels. Various factors can provoke seizures, including epilepsy, brain injuries, infections, genetic predispositions, metabolic imbalances, and substance withdrawal. Identifying the root cause is pivotal for effective treatment. Triggers such as flashing lights, stress, sleep deprivation, hormonal changes, and certain medications can precipitate seizures in susceptible individuals, necessitating recognition and avoidance for seizure management. Treatment strategies focus on seizure control and enhancing quality of life, often employing antiepileptic medications, lifestyle adjustments, and occasionally surgical interventions for resistant cases. Comprehensive seizure management includes educating patients and caregivers on seizure first aid, implementing safety measures, and addressing psychosocial aspects for holistic support. Analyzing seizures requires a thorough evaluation encompassing their classification, causes, triggers, and management approaches to deliver optimal care and assistance to those impacted by these neurological events.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States